Objective: To investigate the associations between age, vascular health, and Alzheimer disease (AD) imaging biomarkers in an elderly sample. Methods: We identified 430 individuals along the cognitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging (MRI) scans from the population-based Mayo Clinic Study of Aging. A subset of 329 individuals had fluorodeoxyglucose (FDG) PET. We ascertained presently existing cardiovascular and metabolic conditions (CMC) from health care records and used the summation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke as a surrogate for vascular health. We used global amyloid from Pittsburgh compound B PET, entorhinal cortex tau uptake (ERC-tau) from tau-PET, and neurodegeneration in AD signature regions from MRI and FDG-PET as surrogates for AD pathophysiology. We dichotomized participants into CMC 5 0 (CMC 2 ) versus CMC > 0 (CMC 1 ) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. Results: CMC 1 participants had significantly greater neurodegeneration than CMC 2 participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau. Interpretation: Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. ANN NEUROL 2017;82:706-718 A ge is a significant driver of decline in vascular health 1 and increase in Alzheimer disease (AD) pathophysiology (ADP). 2 Several studies have shown that decline in vascular health has a significant impact on brain health and also increases the risk of AD dementia. [3] [4] [5] [6] [7] [8] [9] Although it is well known that the impact of vascular health on cognitive performance is mediated via vascular brain injury, 6,8 the direct impact of vascular health on each individual ADP process, namely amyloid, tau, and AD-associated neurodegeneration, is poorly understood and the interrelationships between ADP and vascular health are highly debated. We hypothesized that the associations between ADP biomarkers and vascular risk factors can be disentangled by considering the direct and indirect effects of age, sex, and apolipoprotein E (APOE) on each of these View this article online at wileyonlinelibrary.com.
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) and tested for age-adjusted group differences in AD biomarkers. Using structural equation models (SEMs), we assessed the impact of vascular health on AD biomarker cascade (amyloid leads to tau leads to neurodegeneration) after considering the direct and indirect age, sex, and apolipoprotein E effects. Results: CMC 1 participants had significantly greater neurodegeneration than CMC 2 participants but did not differ by amyloid or ERC-tau. The SEMs showed that (1) vascular health had a significant direct and indirect impact on neurodegeneration but not on amyloid; and (2) vascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-tau. Interpretation: Vascular health had quantifiably greater impact on neurodegeneration in AD regions than on amyloid deposition. Longitudinal studies are warranted to clarify the relationship between tau deposition and vascular health. ANN NEUROL 2017; 82:706-718 A ge is a significant driver of decline in vascular health 1 and increase in Alzheimer disease (AD) pathophysiology (ADP). 2 Several studies have shown that decline in vascular health has a significant impact on brain health and also increases the risk of AD dementia. [3] [4] [5] [6] [7] [8] [9] Although it is well known that the impact of vascular health on cognitive performance is mediated via vascular brain injury, 6, 8 the direct impact of vascular health on each individual ADP process, namely amyloid, tau, and AD-associated neurodegeneration, is poorly understood and the interrelationships between ADP and vascular health are highly debated. We hypothesized that the associations between ADP biomarkers and vascular risk factors can be disentangled by considering the direct and indirect effects of age, sex, and apolipoprotein E (APOE) on each of these processes. Therefore, in this paper we aimed to investigate the association between age, vascular health, and ADP imaging biomarkers in a population-based elderly sample using 2 separate methods to understand these complex associations. In the first set of analyses, we evaluated the impact of vascular health on each of the AD biomarkers after accounting for the effects of age (both linear and nonlinear). In the second set of analyses, we evaluated these associations by making assumptions about the sequence of AD biomarkers based on the widely accepted amyloid biomarker cascade, 10 which posits that amyloid deposition accelerates tau deposition, which in turn drives neurodegeneration that underlies cognitive impairment. We undertook this second approach to capture the direct and indirect impact of age and vascular health on each of the ADP biomarkers. The present study included Mayo Clinic Study of Aging (MCSA) participants who had ADP imaging biomarkers. In this paper, we considered the following main imaging surrogates of ADP: (1) amyloid positron emission tomography (PET) imaging using 11 C-Pittsburgh compound B (PiB) PET as a surrogate for cerebral amyloidosis 11 ; (2) tau-PET imaging using 18 F-AV1451-PET (also known as T807 and flortaucipir) as a surrogate for abnormal 3R/4R tau deposition 12 ; and (3) neurodegeneration in AD signature regions using magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG) PET as a surrogate for AD-specific neuronal dysfunction. 13 We specifically looked at vascular health in the recent past, that is, in the 5-year time period prior to the ascertainment of the ADP biomarkers.
Subjects and Methods

Selection of Participants
All participants were enrolled in the MCSA, a population-based study of Olmsted County, Minnesota residents. The Olmsted County population was enumerated using the Rochester Epidemiology Project (REP) medical records-linkage system, 14,15 which allowed us to ascertain vascular health factors from health care records instead of relying on self-report. We included all 430 elderly individuals (age > 60 years) with APOE genotype, vascular health indicators (discussed below), and concurrent imaging (PiB-PET, tau-PET, and MRI scans). At the time of the scans, 389 were cognitively unimpaired, 33 had mild cognitive impairment, 5 were diagnosed with a neurodegenerative disorder (2 with AD and 3 with mixed dementia), and 3 had a missing clinical diagnosis due to incomplete data. A subset of these individuals also had FDG-PET scans (n 5 329), which were included. The complete details of MCSA design and clinical diagnoses criteria were discussed by Petersen et al 16 and Roberts et al. 17 Standard protocol approvals, registrations, and patient consents. These studies were approved by the Mayo Clinic and Olmsted Medical Center institutional review boards. Informed consent was obtained from all participants or their surrogates.
Demographics and APOE
Sex and years of education were obtained at the clinical visit. Age at the time of the MRI scan was considered. APOE genotype (presence of an APOE E4 allele) was determined from blood collected at the clinical visit.
Cognitive Performance
The neuropsychological battery consisted of 9 tests covering 4 cognitive domains, as previously described. 16, 17 A global cognitive summary score was estimated from the z transformation of the average of the 4 domain z scores (executive function, language, memory, and visuospatial performance). : hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke. The specific codes pooled together are tabulated in the Supplementary Material. In addition to using each individual component of vascular health separately, we also computed a composite score (referred here as cardiovascular and metabolic conditions [CMC] ), which represents the summation of the presence or absence of each of these conditions. To reduce the false-positive rates, we required that individuals received 2 codes for any given condition separated by >30 days within the 5-year capture period as done previously by REP investigators. 19, 20 AD Imaging Biomarkers AMYLOID, TAU, AND NEURODEGENERATION ASSESS-MENT FROM PET SCANS. The acquisition and processing details of amyloid PET, tau-PET, and FDG-PET scans acquired on the study participants were discussed in detail by Jack et al. 21 For amyloid PET, we computed the global amyloid load for each subject by calculating median uptake in the prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, and posterior cingulate/precuneus regions of interest (ROIs) divided by the median uptake in the cerebellar crus gray matter ROI.
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For tau-PET, we assessed entorhinal cortex tau uptake (ERCtau) in each individual subject by calculating median uptake in the entorhinal cortex divided by the median uptake in the cerebellar crus and used it as a signature for AD-related tau pathology. 22 We used ERC-tau for 2 reasons: (1) in our recent work, we found that it was the most sensitive region to global amyloid deposition 22 ; and (2) entorhinal cortex (as well as We also report Cohen D-based effect sizes for all variables between the 2 groups. For AD biomarkers and global cognition summary score, Cohen D was calculated using age-adjusted means and standard deviations. In addition, we performed analyses allowing for nonlinear age adjustments from spline curves with knots at 68, 74, and 82 years. We also tested the group differences between all participants dichotomized by the presence and absence of each of the CMC components, that is, hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke. We also conducted sensitivity analyses in only cognitively unimpaired individuals as well as after dichotomizing individuals based on CMC < 2 and CMC 2.
STRUCTURAL EQUATION MODELS.
We conducted path analyses (structural equation models [SEMs] with only manifest, ie, observed variables) using Mplus version 8.0 structural equations software and the R Lavaan package. Path analyses are extensions of regression models, and require a weak causal ordering of the variables to be specified before running any models. They allow us to account for complex relationships between the variables, rather than simply adjusting for confounding variables through ANCOVA. Assuming that the structure is correct (or close; there is reasonable robustness in these analyses), the SEMs should give a cleaner and more detailed picture of the effects. We first fit a saturated model with all possible associations between 5 levels of variables (plotted from left to right), where Level 1 consisted of sex, age at MRI, and APOE4 genotype; Level 2 consisted of the summary CMC measure (vascular health); Level 3 consisted of amyloid deposition; Level 4 consisted of ERC-tau; and Level 5 consisted of neurodegeneration. For the neurodegeneration variable, we only considered neurodegeneration in AD signature regions from MRI in the SEMs, because we did not have FDG-PET scans in the full sample. Sex was added to the model because there are sex differences in the aging process. 25 Each level in the SEM analysis is assumed to come later than preceding levels in a causal framework. Thus, any variable can cause changes to variables lying in higher levels. Any variables lying between variables on a lower and higher level are mediators. The possible causal associations are thus direct effects (arrow directly joins variables), indirect effects (arrows pass through one or more mediators), and total effects (sum of direct and indirect). We pruned the path analysis using goodness of fit measures (Bayesian information criterion, chi-square test of model fit, root mean square error of approximation [RMSEA], Tucker-Lewis Index [TLI] , and Comparative Fit Index [CFI]) and individual p values until all paths in the final model were significant, and the goodness of fit measures indicated that the model fit the observed data well. We checked the pruning using lasso in the R package RegSEM 26 and found that the pruned models were consistent. We report regression coefficients with their associated standard errors and p values. The coefficients give the predicted change in the outcome (higher level) variable per unit increase in the predictor (lower level) variable. Age was coded to give results per 10-year (decade) increase. CMC units correspond to an increase of 1 condition. Amyloid deposition and ERC-tau were first log-transformed to better meet the model assumptions, and then standardized so that a unit increase corresponds to 1 standard deviation. Neurodegeneration was standardized so that a unit increase corresponds to 1 standard deviation and the sign was flipped such that high values are worse, that is, in the same direction as amyloid and tau. We also conducted a sensitivity SEM analysis using all 7 indicators of vascular health as individual predictor variables.
Results
The overall participant characteristics as well as participants dichotomized by CMC are shown in Table 1 . The CMC 1 group was significantly older but did not differ by sex, APOE genotype, education, or global cognition from the CMC 2 group. Figure 1 shows the bar plots of mean number of CMC conditions and AD neuroimaging biomarkers by 5-year increments and illustrates the worsening of each of these variables with age. After age adjustment, amyloid and ERC-tau levels were not significantly different between the CMC 1 and CMC 2 group. On the other hand, FDG-PET uptake and MRI cortical thickness were significantly lower between the CMC 2 and CMC 1 groups. The relative differences between the groups were significantly greater for FDG and MRI in comparison to the amyloid and ERC-tau levels as observed by the magnitude of the effect sizes. Because the association between vascular health and age is fairly linear, the more general analyses that allowed for nonlinear age adjustment produced very similar results for all biomarkers. In the sensitivity analyses with only cognitively unimpaired individuals (Supplementary Tables 1 and 2 ) and when all individuals were dichotomized by CMC 5 2 (Supplementary Table 3 ), we reached similar conclusions. Supplementary Table 4 summarizes the group differences for demographics and cognition between participants dichotomized by the presence and absence of each of the CMC components. Men had a greater frequency of cardiac arrhythmias and coronary artery disease. None of the CMC components was significantly associated with APOE4 carrier status. Education levels were significantly lower in individuals with stroke and congestive heart failure compared to those without these conditions. Cognition was significantly lower or approached significance for cardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke but not for hyperlipidemia or hypertension. Table 2 summarizes the AD biomarker results for all individuals when they were dichotomized by the presence and absence of each CMC component. For each of the CMC components, amyloid load was not significantly different between participants with and without the risk factor. ERC-tau was slightly higher in those with hyperlipidemia versus those without hyperlipidemia (p 5 0.070) as well as those with coronary artery disease and without coronary artery disease (p 5 0.075). Neurodegeneration biomarkers (FDG-PET and/or MRI) were significantly (p < 0.05) worse for 5 of the 7 vascular health indicators (hyperlipidemia, cardiac arrhythmias, coronary artery disease, congestive heart failure, and diabetes). Supplementary Table 2 summarizes the results for only cognitively unimpaired individuals and shows similar results.
The results of the significant associations in the path analyses are shown in Figure 2 . The final model fit the data very well. The chi-square test of model fit (comparing to a saturated model) was not significant (p 5 0.24), the RMSEA (0.026) was <0.05, and the TLI (0.990) and CFI (0.996) were both >0.95. Please note that the coefficients across all arrows cannot be compared, but coefficients on arrows going to a particular outcome are comparable. These associations are split by paths to outcome variables (vascular health and AD biomarkers) in Figure 3 . We have included Table 3 with the complete direct and indirect effects observed in Figure 2. Here we describe the predictors of each of the outcomes in a stepwise fashion:
1. Age (coefficient 5 0.616) and being male (coefficient 5 0.287) were significant direct predictors of vascular health. 2. Age (coefficient 5 0.446) and APOE4 (coefficient 5 0.612) were significant direct predictors of amyloid deposition. 3. CMC and amyloid were significant direct predictors of ERC-tau, with the effect of amyloid on ERC-tau (coefficient 5 0.555) being larger than the effect of CMC on ERC-tau (coefficient 5 0.067). Age had both an indirect effect through CMC (coefficient 5 The results of the sensitivity SEM analysis results with all 7 indicators of vascular health are shown in Figure 4 . The final model in this case fit the data fairly well. The RMSEA (0.055) was close to 0.05, and the TLI (0.894) and CFI (0.929) were both close to 0.90, although below 0.95. The chi-square test in this model does not apply in the usual manner. Simple theoretically reasonable additions to the model did not appreciably improve the fit. Of the 7 variables, diabetes, cardiac arrhythmias, congestive heart failure, and hyperlipidemia were significant predictors of AD biomarkers. Among these, only hyperlipidemia was a significant predictor of ERC-tau and the rest were significant predictors of neurodegeneration. None of the vascular health indicators was a significant predictor of amyloid deposition.
Discussion
The main findings of this paper were that (1) poor vascular health does not significantly impact amyloid deposition, but has a significant direct and indirect effect on AD neurodegeneration in an elderly sample; and (2) there was a significant impact of vascular health on ERC-tau that was driven by hyperlipidemia, but the effect was smaller than the association of amyloid with ERC-tau.
Age is a significant predictor for vascular health, as observed in Figures 1 and 2 . Aging acts through a number of biological mechanisms at the cellular or tissue level that may lead to multisystem loss of reserve and function, as discussed by Fabbri et al. 27 This multisystem homeostatic dysregulation leads to several chronic diseases, including cardiovascular and metabolic conditions. 27, 28 Age is also a significant predictor for brain changes. Amyloid and tau pathologies 2 as well as brain shrinkage (even without AD pathologies) 23 increase with age. Therefore, accounting for age in the first set of analyses (see Tables 1 and 2 ) allowed us to determine whether vascular health and ADP were associated independently of the impact of age on each of these factors. Additionally, the SEM analyses allowed us to simultaneously look at the direct and indirect effects of age on each of the variables of interest and also take into consideration the stepwise progression of AD processes, which is not possible with group comparisons.
Predictors of Vascular Health
In addition to age, being male was a significant predictor of vascular health (see Figs 2 and 3A). As seen in the Supplementary Tables, there was a greater frequency of men among those with cardiac arrhythmias and coronary artery disease, consistent with the literature, 29 and this may have driven the path from sex to vascular health. In both the sets of analyses, we did not find an association between APOE4 and vascular health. 
Predictors of Amyloid Deposition
As expected, APOE4 along with age were significant predictors of amyloidosis 30 in Figures 2 and 3B . In both the analyses, we did not find an association between poor vascular health and amyloid deposition. In the SEM analyses (see Fig 2) and Table 1 , we specifically tested whether vascular health has an impact on amyloid and did not find evidence for an association. In the sensitivity SEM analysis (see Fig 4) as well as Table 2 , we also tested the impact of each vascular health indicator on amyloid deposition and did not find evidence for an association between vascular health and amyloid deposition. These results are consistent with a systematic review by Chui et al showing that there is insufficient evidence to support that vascular risk increases amyloid pathology. 5 One major issue that may have contributed to the debate in the literature could be the confounding effect of age seen on both vascular health and AD biomarker variables. Amyloid accumulation in the brain is due to the imbalance between amyloid production and clearance. Although we found no significant association between vascular health and amyloid accumulation in early stages of the disease, this does not preclude the possibility that in later stages of the disease both processes may interact through mechanisms such as poor clearance of extracellular Ab through the glymphatic system 31, 32 or large extent of hypoperfusion and hypoxia contributing to greater amyloid accumulation. 33 
Predictors of Tau Deposition
Amyloid was the strongest predictor of ERC-tau, as expected. 10 We also found evidence for an amyloidindependent direct pathway from CMC to ERC-tau (see Figs 2 and 3C). In Table 2 , we found weak associations between vascular health and tau deposition, as suggested by the group differences seen with hyperlipidemia (p 5 0.07) and coronary artery disease (p 5 0.075). From the sensitivity SEM analyses in Figure 4 , we found that the primary predictor of the association between vascular health and ERC-tau seen in Figure 2 was hyperlipidemia. In our recent study 34 as well as this paper, we found evidence that lipids play an important role in the pathogenesis of processes upstream of AD neurodegeneration. Using tau-PET and amyloid PET together here, we were able to further discern that tau deposition is specifically influenced by hyperlipidemia. Cholesterol accumulation and impaired cholesterol metabolism have been found to be toxic to neuronal cells and proposed to be involved in the generation of tau. 35 Additionally, statins have been shown to reduce the neurofibrillary tangle burden in animal models 36, 37 and modulate tau phosphorylation in humans. 38, 39 Although we found a small effect of poor vascular health, specifically hyperlipidemia on tau deposition, further longitudinal studies are needed to clarify the mechanisms through which these risk factors may increase tau deposition, which will be the focus of our future studies. We did not detect a direct pathway from age to tau consistent with the primary age-related tauopathy (PART) hypothesis. 40 The effect of age on ERC-tau is much smaller compared to the effect of amyloid on ERCtau, because PART (abnormal tau in the absence of amyloidosis) is observed only in advanced ages compared to ages at which abnormal amyloid and tau are observed and in only a smaller proportion of elderly (compared to elderly with both amyloid and tau pathologies). Because our model structure forces amyloid to come before tau, this could possibly overwrite any direct effect of age, especially if the direct effect is small relative to the amyloid effect.
Predictors of Neurodegeneration
Age, being male, ERC-tau, and poor vascular health had a significant direct impact on neurodegeneration. Age (even without amyloid) and being male have been shown to be associated with neurodegeneration. 23 Animal models support that there is age-related neural structure alteration, specifically reductions in spine density and reductions in neuronal arborization that reflect early neurodegeneration. 41, 42 Tau deposition and neurodegeneration are well known to be tightly coupled. 10 Although studies show that poor vascular health is associated with increased risk of AD 43, 44 as well as neurodegeneration, 45, 46 we found evidence for a significant direct and indirect impact of vascular health on AD neurodegeneration that was not mediated by amyloid deposition. This suggests that vascular health lowers the threshold for dementia by independently impacting neurodegeneration and to some extent ERC-tau, but has minimal direct impact on amyloidosis. 5, 47 In Figure 4 , we found that among all the variables, the primary predictors of neurodegeneration among the CMC variables were congestive heart failure, diabetes, and cardiac arrhythmias.
AD Biomarker Cascade
Each of the AD biomarkers (tau deposition, amyloid deposition, and neurodegeneration) can be initiated independently, but there is sufficient evidence supporting the AD biomarker cascade hypothesis that amyloid deposition accelerates tau deposition, which in turn is closely associated with neurodegeneration and cognitive decline in AD. An important point to consider is that we included the complete spectrum of population-based individuals for the SEMs. If we had included only cognitively unimpaired individuals, we would be excluding individuals in whom there was sufficient pathology (due to amyloid, tau, neurodegeneration, and vascular risk factors) to cause cognitive impairment, which would create significant bias when modeling the entire disease process. Although we did not test the biomarker cascade hypothesis but assumed a fixed ordering in this paper, we found evidence for the stepwise association of amyloid on ERC-tau and ERC-tau on AD pattern neurodegeneration. We conducted additional sensitivity analyses and found that (1) amyloid and tau at the same level had a poor model fit and (2) tau before amyloid resulted in a model with no direct or indirect effect of amyloid on neurodegeneration, providing support for the ordering we assumed in the paper. The SEM approach we took here was valuable because it allowed us to investigate the independent impact of vascular health on AD biomarkers after accounting for the interrelationships between age and AD biomarkers as well as between each of the AD biomarkers.
Strengths and Limitations
A major strength of this study is the availability of electronic health records through the REP from which our MCSA study participants are sampled and which also allowed us to ascertain vascular health prior to the scans. Although the use of health care records might be considered a limitation, the requirement of 2 clinical visits separated by 30 days limits false positives; also, previous papers that validated REP-based ICD-9 codes support the ascertainment of vascular health from REP-based health care records. [48] [49] [50] [51] There were also other limitations to this study. We only focused on an amyloidsensitive tau region seen in the elderly. 22 The results may be different for tau-PET uptake in different regions and in atypical AD. We also undertook a global approach here with cross-sectional (vascular health) diagnosis data instead of looking at the mechanistic underpinnings of each vascular health indicator along with blood serum biomarkers 9, 52 and studying these predictors and outcomes in a longitudinal framework to further understand the casual associations. However, we strongly believe that such a bird's-eye view is important and will be helpful in guiding the development of future hypotheses.
